
Minister of Health Mónica García announces that HIPRA's COVID-19 vaccine will be available for the 2025–2026 vaccination campaign

During her first visit to the new HIPRA Campus, the Minister emphasized the company's role in European strategic autonomy and global public health

Girona, 7 November 2025 – The Minister of Health, Mónica García, visited today the new HIPRA Campus in Aiguaviva (Girona), the company's biotechnological innovation center that is becoming one of Europe's leading hubs for research, development, and production of vaccines and biotechnological products for global public health. The visit included a tour of the facilities, covering an area of 114,000 m², which house production buildings as well as corporate and research and development areas. **The Minister also learned about HIPRA's progress in public health and its contribution to strengthening Europe's health autonomy and preparedness for future pandemics.**

HIPRA's COVID-19 vaccine available this campaign

During the visit, the Minister received first-hand information about the latest updates on HIPRA's COVID-19 vaccine adapted to the LP.8.1 variant, **which will be available in Spain during the 2025–2026 vaccination campaign.**

“Soon we will have the vaccine available in health centers. It is a source of pride for our country, for innovation, and for Europe and Spain's strategic autonomy to have an industry capable of developing the entire value chain—from research to production and commercialization,” the Minister announced.

Produced entirely in Spain, the HIPRA COVID-19 vaccine represents a decisive step toward European health autonomy, offering an effective, safe, and accessible alternative against COVID-19. **The European Commission has signed a framework agreement with HIPRA for the acquisition of up to 4 million doses over two years**, ensuring that Europe maintains its own production capacity for future vaccination campaigns.

HIPRA, a key partner for European strategic autonomy and global public health

The Minister also **highlighted the importance of the new HIPRA Campus for the future of biotechnology and the need for companies like HIPRA, which combine science, technology, and public commitment to strengthen Spain and Europe's strategic health autonomy.**

During the visit, Maria del Mar Nogareda, Vice President of HIPRA, stated: “The Minister’s visit highlights the effort we are making from Spain to ensure our capacity to respond to global health challenges and to prepare for potential pandemics. Our goal is clear: **to drive innovation from Europe, strengthen strategic autonomy, and provide biotechnological solutions such as vaccines** that protect both people and animals.”

The new campus, **which will create over 1,000 direct jobs and more than 2,000 indirect jobs once completed**, is one of the largest biotechnology investments in Europe. **With an investment of over €500 million**, HIPRA Campus features state-of-the-art facilities. In its first phase, **it already includes 28,000 m²** dedicated to R&D, production, and corporate areas—tripling the company’s capacity in research and development for both animal and human health. HIPRA’s commitment to prevention and innovation reflects its continued dedication to the “One Health” approach and its desire to contribute, through its expertise and knowledge, to a healthier and more sustainable world.

HIPRA, a key partner in the “One Health” approach

HIPRA plays an essential role in strengthening Europe’s health capacity through the “**One Health**” approach, which recognizes the interconnection between human, animal, and environmental health. Among its initiatives is the **EU FAB** project, for which **the company was selected to guarantee flexible production capacity in emergency situations**. It also leads the **SPEEDCELL** project, part of EU4Health, aimed at improving Europe’s agility and technological readiness by **reducing to just 100 days the time required to develop new vaccines in future health crises**.

About HIPRA

HIPRA is a biotechnological pharmaceutical company focused on prevention for both animal and human health (One Health), offering a wide range of highly innovative vaccines and advanced diagnostic services.

With its claim “**Building immunity for a healthier world,**” HIPRA reaffirms its commitment to providing solutions that enhance global health.

The company has a strong international presence, **with 40 subsidiaries, 3 R&D centers, and 6 production sites** strategically located in Europe (Spain) and America (Brazil). Its extensive international distribution network reaches nearly 100 countries across five continents.

Research and development are at the core of its expertise. HIPRA **invests more than 15% of its annual revenue in R&D** activities focused on applying the latest scientific advances to develop innovative, high-quality vaccines. HIPRA’s portfolio includes vaccines based on a variety of technological platforms, with R&D teams working with a broad range of technologies and biological modalities.

To add value to its vaccination expertise, the company also develops medical devices and traceability services for animal health.

Press contacts

Irene Calle – icalle@harmon.es – M. +34 609 873 052

José María Nieto – jnieto@harmon.es – M. +34 689 186 062